Considering the known contribution of FABP5 to PC progression, these findings provide additional evidence that FABP5 inhibition is a sound therapeutic strategy to reduce tumor growth and metastasis and potentially blunt the development of taxane resistance. The gene discussed is FABP5; the disease is pachyonychia congenita.